NCT03291210 is a NA clinical trial of normal inspired oxygen fraction in Troponin, sponsored by Seoul National University Hospital.

Who is sponsoring NCT03291210?

NCT03291210 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT03291210?

Interventions in NCT03291210: normal inspired oxygen fraction, high inspired oxygen fraction.

Is NCT03291210 still recruiting?

NCT03291210 is currently completed. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT03291210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

O2 Tension During TAVI

Completed NA Last updated 19 July 2022

What this trial tests

NA trial testing normal inspired oxygen fraction in Troponin in 72 participants. Completed in 18 July 2022.

Timeline

18 October 2017

Primary endpoint
6 April 2022

18 July 2022

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	72
Start date	18 October 2017
Primary completion	6 April 2022
Estimated completion	18 July 2022
Sites	1 location across South Korea

Drugs / interventions tested

normal inspired oxygen fraction
high inspired oxygen fraction

Conditions studied

Troponin — all drugs for Troponin →

Sponsor

Seoul National University Hospital

Who can join

Adults 20 to 99, any sex, with Troponin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hyperoxemia can produce various complications including oxidative stress and myocardial injury. We hypothesized that the normoxic group would have lower myocardial injury compared to hyperoxic group after transcatheter aortic valve replacement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of low versus high inspired oxygen fraction on myocardial injury after transcatheter aortic valve implantation: A randomized clinical trial.
Cho YJ, Hyeon C, Nam K, Lee S, et al · · 2023 · PMID 37531368 · DOI 10.1371/journal.pone.0281232

Verify or expand the search:

Other recruiting trials for Troponin

Currently open trials in the same condition.

NCT06853626 — One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care · NA · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03291210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03291210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing